About CPP-109
CPP-109 is Catalyst's designation for vigabatrin, a potential treatment for cocaine and other drug addictions. The FDA has accepted Catalyst's Investigational New Drug application to conduct clinical trials in the United States of CPP-109 for addictions (initially cocaine and methamphetamine) and has granted Fast Track status to CPP-109. To date, Catalyst has supported three completed human trials in Mexico. For information on those trials, see the links below.
Vigabatrin, also known as gamma vinyl-GABA or GVG, is marketed as Sabril® outside of North America by Sanofi-Aventis and within North America by Lundbeck Inc. Sabril is available in tablet and powder forms and used in combination therapy for specific types of epilepsy and alone in the management of infantile spasms (West Syndrome).
CPP-109 works for short-term treatment without the apparent side effects typically associated with GABA agonists. Targeting brain GABAergic systems with drugs such as CPP-109 is a potentially effective treatment for cocaine, methamphetamine and other substance dependencies.
| Human brain scans showing the effect of cocaine use on brain metabolism courtesy Brookhaven National Laboratory | ||
|---|---|---|
 |  |  |
| Normal brain metabolism | Brain metabolism after 10 days of cocaine use | Brain metabolism after 100 days of cocaine use |
Read about our third Mexican trial:
- The American Journal of Psychiatry, November 2009, article (PDF file) and editorial (PDF file)
- Rodman & Renshaw expert panel, transcript (PDF file)
- Catalyst press release
Read about our second Mexican trial (PDF file).
Read about our first Mexican trial (PDF file).
Read a pilot study on CPP-109 and ocular safety (PDF file).
CPP-109
Place cursor next to bottom molecule to see animation.
Molecular models courtesy
Dr. Joseph W. Lauher,
SUNY Stony Brook